The Advanced Research Projects Agency for Health (ARPA-H) has launched a $144 million initiative aimed at understanding and mitigating the impact of microplastics on human health, signalling a more coordinated federal push into a fast-emerging risk area.
The programme—Systematic Targeting Of MicroPlastics (STOMP)—will take a phased approach to address what remains a largely unquantified and poorly understood threat. While microplastics have been detected across multiple human organs, the clinical implications and pathways for intervention remain unclear.
Phase one will focus on foundational science. Researchers will investigate how microplastics accumulate within the human body and establish a standardised method for measuring their presence. A key deliverable will be the development of a clinical-grade diagnostic test capable of quantifying an individual’s microplastic burden—laying the groundwork for population-level monitoring and future intervention strategies.
The second phase shifts toward treatment, with efforts centred on identifying safe and effective methods to remove microplastics from the body. This marks a significant step beyond detection, pushing into the more complex territory of remediation.
“Microplastics are in every organ we look at — in ourselves and in our children. But we don’t know which ones are harmful or how to remove them,” said ARPA-H Director Alicia Jackson, PhD. “Nobody wants unknown particles accumulating in their body. The field is working in the dark. STOMP is turning on the lights.”
The announcement coincides with broader regulatory momentum. On the same day, the Environmental Protection Agency (EPA) confirmed it is adding microplastics to its proposed list of drinking water contaminants—an update that will inform how local authorities assess and manage water safety risks.
Taken together, the initiative reflects a shift from fragmented research toward a more structured, translational effort—one that spans detection, standardisation, and ultimately intervention. For healthcare systems and policymakers, the challenge now will be turning emerging evidence into actionable guidance before exposure risks further outpace understanding.
Click here for the original news story.